コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 r inhibiting the downstream signaling of the vascular endothelial growth factor receptor.
2 hat is at least partly distinct from that of vascular endothelial growth factor receptor.
3 inase inhibitor that preferentially inhibits vascular endothelial growth factor receptors.
5 single-nucleotide polymorphism (SNP) in the vascular endothelial growth factor receptor 1 (VEGFR-1/F
6 rognostic significance, including Ki67, p53, vascular endothelial growth factor receptor 1 (VEGFR1) a
7 certain inflammatory cells--might depend on vascular endothelial growth factor receptor 1 (VEGFR1) a
8 l approaches, we show that the expression of vascular endothelial growth factor receptor 1 (VEGFR1) b
10 t and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1),
11 rane-proximal seventh Ig-like domain (D7) of vascular endothelial growth factor receptor 1 (VEGFR1),
12 porter assay and the increased expression of vascular endothelial growth factor receptor 1 (VEGFR1),
13 ssion of CXCR7 expression and recruitment of vascular endothelial growth factor receptor 1 (VEGFR1)-e
14 This study sought to determine whether a Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-s
15 This study sought to determine whether a vascular endothelial growth factor receptor 1 (VEGFR1)-s
16 th factor receptor 2 antibody) or icrucumab (vascular endothelial growth factor receptor 1 antibody)
17 nolase, placental growth factor, and soluble vascular endothelial growth factor receptor 1 levels wer
18 rived hematopoietic progenitors that express vascular endothelial growth factor receptor 1 mobilize i
19 ial growth factor A (VEGF-A) and the soluble vascular endothelial growth factor receptor 1 molecule,
20 niche formation (evidenced by a decrease in vascular endothelial growth factor receptor 1 positive (
21 luble fms-like tyrosine kinase 1 (sFlt-1) of vascular endothelial growth factor receptor 1 secreted f
22 ediated transcriptional induction of Vegfr1 (vascular endothelial growth factor receptor 1) is depend
23 vascular endothelial growth factor A and D; vascular endothelial growth factor receptor 1, 2, and 3;
24 -1), an alternatively spliced variant of the vascular endothelial growth factor receptor 1, induces a
26 Angiogenic factors promote mobilization of vascular endothelial growth factor receptor 1-positive h
27 and show that PlGF acts through Nrp1-and not vascular endothelial growth factor receptor 1-to promote
30 ochemistry; with placental growth factor and vascular endothelial growth factor receptors 1 and 2 usi
31 her motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3
32 of tyrosine kinase activity associated with vascular endothelial growth factor receptors 1, 2, and 3
33 tigational, orally bioavailable inhibitor of vascular endothelial growth factor receptors 1, 2, and 3
40 FcgammaR results in the secretion of soluble vascular endothelial growth factor receptor-1 (VEGFR-1/s
43 Soluble Flt-1 (sFlt-1; also known as soluble vascular endothelial growth factor receptor-1 [VEGFR-1])
44 ith melanoma stem cell-associated nestin and vascular endothelial growth factor receptor-1 also was d
45 Bone marrow-derived (BMD) cells that express vascular endothelial growth factor receptor-1 and very l
46 tease-resistant core fragment comprising the vascular endothelial growth factor receptor-1 binding si
47 the same was true for the finding of higher vascular endothelial growth factor receptor-1 expression
49 f tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -
52 an oral DNA minigene vaccine against murine vascular endothelial growth factor receptor 2 (FLK-1), a
53 beta, epidermal growth factor receptor, and vascular endothelial growth factor receptor 2 (Flk-1), b
55 2.0-5.8; Ptrend = 1.1 x 10(-6)), and soluble vascular endothelial growth factor receptor 2 (sVEGFR2;
56 NF-kappaB) pathways and the up-regulation of vascular endothelial growth factor receptor 2 (VEGF-R2)
57 ds to an abnormal and persistent increase in vascular endothelial growth factor receptor 2 (VEGF-R2)
58 lly as epithelial growth factor receptor and vascular endothelial growth factor receptor 2 (VEGFR-2)
59 ing, BVZ pharmacokinetics, and estimation of vascular endothelial growth factor receptor 2 (VEGFR-2)
60 In murine embryonic stem cells, the onset of vascular endothelial growth factor receptor 2 (VEGFR-2)
61 that targets the key angiogenesis receptors vascular endothelial growth factor receptor 2 (VEGFR-2)
62 on of custom designed imaging probes against vascular endothelial growth factor receptor 2 (VEGFR-2)
64 ing CD144 or E-selectin, and EPCs expressing vascular endothelial growth factor receptor 2 (VEGFR-2),
65 pyroptosis, improves EC survival mediated by vascular endothelial growth factor receptor 2 (VEGFR-2),
67 owth factor receptor 2-IIIb (FGFR2b) and the vascular endothelial growth factor receptor 2 (VEGFR2) a
69 either hematopoietic cell loss of FGFR1/2 or vascular endothelial growth factor receptor 2 (Vegfr2) h
70 this disease is resistant to treatment with vascular endothelial growth factor receptor 2 (VEGFR2) i
71 dimer known to have a high affinity for the vascular endothelial growth factor receptor 2 (VEGFR2) i
73 ation of Cdc42 in ECs decreased the level of vascular endothelial growth factor receptor 2 (VEGFR2) p
75 protein tyrosine phosphatase (SHP)-1 to the vascular endothelial growth factor receptor 2 (VEGFR2) s
76 tyrosine kinase (Etk), which trans-activates vascular endothelial growth factor receptor 2 (VEGFR2) t
77 as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) t
78 egulate permeabilizing responses directed by vascular endothelial growth factor receptor 2 (VEGFR2),
79 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2),
80 ptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2),
81 several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2),
84 We apply this strategy to the isolation of vascular endothelial growth factor receptor 2 (VEGFR2)-b
85 enic factors, PRAK is activated by p38 via a vascular endothelial growth factor receptor 2 (VEGFR2)-d
86 ultrasonography (US) by using clinical-grade vascular endothelial growth factor receptor 2 (VEGFR2)-t
87 ocking the placental growth factor (PlGF) or vascular endothelial growth factor receptor 2 (VEGFR2).
88 ; P=3.8 x 10(-11)), upstream of KDR encoding vascular endothelial growth factor receptor 2 (VEGFR2).
89 rent binding to the alpha2beta1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2).
90 arises from a population that expresses the vascular endothelial growth factor receptor 2 (VEGFR2, F
91 osine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 and epider
92 showed that GA inhibited the activations of vascular endothelial growth factor receptor 2 and its do
93 nd the angiogenic receptor tyrosine kinases, vascular endothelial growth factor receptor 2 and platel
94 Shc activation requires the tyrosine kinases vascular endothelial growth factor receptor 2 and Src.
95 r docetaxel in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody)
96 ction, led to a significant up-regulation of vascular endothelial growth factor receptor 2 expression
97 have a significantly lower proliferation and vascular endothelial growth factor receptor 2 expression
98 erns of epidermal growth factor receptor and vascular endothelial growth factor receptor 2 expression
99 discoveries point to the key role played by vascular endothelial growth factor receptor 2 in control
102 ion was inhibited by rapamycin and SU5416 (a vascular endothelial growth factor receptor 2 inhibitor)
103 receptor 1 kinase inhibitor) and oxindole (a vascular endothelial growth factor receptor 2 kinase inh
104 s (Lm), we fused polypeptides from the mouse vascular endothelial growth factor receptor 2 molecule (
105 ur study provides insights into how FLT1 and vascular endothelial growth factor receptor 2 signaling
106 nsity, endothelial nitric oxide synthase/Akt/vascular endothelial growth factor receptor 2 signaling,
107 of endothelial cells largely by antagonizing vascular endothelial growth factor receptor 2 signaling.
108 endothelial cells, we immunized against host vascular endothelial growth factor receptor 2 to fight t
110 repressor engrailed repressed expression of Vascular Endothelial Growth Factor Receptor 2, a marker
111 uantification of subsets coexpressing CD133, vascular endothelial growth factor receptor 2, and chemo
112 4, alpha-smooth muscle actin, CD31, phospho-vascular endothelial growth factor receptor 2, and p42/4
113 of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearr
114 eas murine endothelial cells expressed CD31, vascular endothelial growth factor receptor 2, and von W
115 murine monocytes expressed F4/80, CD31, and vascular endothelial growth factor receptor 2, but neith
117 injection of neutralizing antibodies against vascular endothelial growth factor receptor 2, CCR3, CC
118 Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and
119 genes, namely matrix metalloproteinase 1 and vascular endothelial growth factor receptor 2, were nega
120 ors are possibly involved in mobilization of vascular endothelial growth factor receptor 2-positive e
127 by an endothelial nitric oxide synthase/Akt/vascular endothelial growth factor receptor 2/oxidative
128 67, vascular endothelial growth factors A/C, vascular endothelial growth factor receptors 2/3, angiop
130 (n = 22) or a truncated soluble form of the vascular endothelial growth factor receptor-2 (truncated
131 ed to a dose- and time-dependent decrease in vascular endothelial growth factor receptor-2 (VEGFR-2)
132 elet-derived growth factor receptor-beta and vascular endothelial growth factor receptor-2 (VEGFR-2)
133 nd evaluated two compounds that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2)
134 nce of a splice variant of the gene encoding vascular endothelial growth factor receptor-2 (Vegfr-2)
135 tion of phospholipase Cgamma1 (PLCgamma1) by vascular endothelial growth factor receptor-2 (VEGFR-2)
136 tified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2)
139 h 6 different antibodies [anti-CD34, -CD31, -vascular endothelial growth factor receptor-2 (VEGFR-2),
140 rs for the receptor tyrosine kinases MET and Vascular Endothelial Growth factor Receptor-2 (VEGFR-2).
145 uster of differentiation 34 (CD34+) or CD34+/vascular endothelial growth factor receptor-2 (VEGFR2+)
146 by this chemokine requires the activation of vascular endothelial growth factor receptor-2 (VEGFR2/fe
147 uced angiogenesis requires the activation of vascular endothelial growth factor receptor-2 (VEGFR2/Fl
148 e switch from signal transducing full-length vascular endothelial growth factor receptor-2 (VEGFR2/KD
149 human immunoglobulin G1 antibody that binds vascular endothelial growth factor receptor-2 and blocks
150 hrough a nonclassical pathway dependent upon vascular endothelial growth factor receptor-2 and downst
151 Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epider
152 not PKD1, was required for the expression of vascular endothelial growth factor receptor-2 and fibrob
153 part through modulation of the expression of vascular endothelial growth factor receptor-2 and fibrob
154 naling, known to induce Notch, by repressing vascular endothelial growth factor receptor-2 and neurop
155 stimulated macrophages were able to activate vascular endothelial growth factor receptor-2 and the PI
156 ated the JAK/STAT-dependent up-regulation of vascular endothelial growth factor receptor-2 by sIL-6R
157 ctor increased, whereas endoglin and soluble vascular endothelial growth factor receptor-2 decreased
158 4 and subsets coexpressing CD133, CXCR4, and vascular endothelial growth factor receptor-2 epitopes.
159 lar endothelial growth factor expression and vascular endothelial growth factor receptor-2 expression
160 cell surface expression of CD133, CD34, and vascular endothelial growth factor receptor-2 in 110 pat
161 lo[2,1-f][1,2,4]triazine-based inhibitors of vascular endothelial growth factor receptor-2 kinase is
162 fluorescent protein under the control of the vascular endothelial growth factor receptor-2 promoter.
163 sis by altering alpha(v)beta(3) integrin and vascular endothelial growth factor receptor-2 traffickin
164 d association/dissociation rate constants of vascular endothelial growth factor receptor-2 with respe
165 on of NANOG which mediates the expression of vascular endothelial growth factor receptor-2, also know
166 od mononuclear cells expressing CD34, CD133, vascular endothelial growth factor receptor-2, and chemo
168 rmal vessels in mammary tumours, by blocking vascular endothelial growth factor receptor-2, improves
169 les directed against various targets such as vascular endothelial growth factor receptor-2, vascular
172 sh the existence of a new soluble isoform of vascular endothelial growth factor receptor 3 (sVEGFR-3)
173 ngiogenesis by monoclonal antibodies against vascular endothelial growth factor receptor 3 (VEGFR-3)
174 s before and after 8 weeks of treatment with vascular endothelial growth factor receptor 3 (VEGFR-3)
175 tain the expression of the lymphatic markers vascular endothelial growth factor receptor 3 (VEGFR-3)
177 Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 (VEGFR-3)
178 delivery of mF4-31C1, a specific antagonist vascular endothelial growth factor receptor 3 (VEGFR-3)
181 used mice bearing one inactivated allele of vascular endothelial growth factor receptor 3 (VEGFR3) w
182 ibitor, blocked several receptors, including vascular endothelial growth factor receptor 3 (VEGFR3),
183 rs are chaotic and poorly formed and express vascular endothelial growth factor receptor 3 (VEGFR3),
184 potential interaction between PTPN14 and the vascular endothelial growth factor receptor 3 (VEGFR3),
185 let/endothelial cell adhesion molecule 1 and vascular endothelial growth factor receptor 3 (VEGFR3).
188 tic markers (prospero homeobox protein 1 and vascular endothelial growth factor receptor 3) as well a
189 l endothelial hyaluronan receptor 1-positive vascular endothelial growth factor receptor 3-positive l
190 Intramyocardial-targeted delivery of the vascular endothelial growth factor receptor 3-selective
192 was, in part, associated with inhibition of vascular endothelial growth factor receptor-3 (VEGFR-3)
193 2 primary mediators of lymphangiogenesis are vascular endothelial growth factor receptor-3 (VEGFR-3)
196 ed by dexamethasone but not by inhibition of vascular endothelial growth factor receptor-3 signaling
197 tigate whether combined blockade of VEGFR-3 (vascular endothelial growth factor receptor-3) and VLA-1
198 of the lymphatic marker genes podoplanin and vascular endothelial growth factor receptor-3, which is
199 poietic cells (CD45), and mesenchymal cells (vascular endothelial growth factor receptor and desmin).
200 Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epiderma
201 b, targeting rearranged during transfection, vascular endothelial growth factor receptor and epiderma
202 andetanib is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epiderma
203 vanib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and fibrobla
204 ed receptor tyrosine kinase inhibitor of the vascular endothelial growth factor receptor and multiple
205 y affect two independent downstream targets, vascular endothelial growth factor receptor and p38 MAPK
206 nhibited the tyrosine kinase activity of the vascular endothelial growth factor receptor and the plat
207 sine kinase inhibitors that target RET, plus vascular endothelial growth factor receptors and additio
208 years, tyrosine kinase inhibitors targeting vascular endothelial growth factor receptors and RET (re
209 , a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epiderm
210 ndetanib, a selective oral inhibitor of RET, vascular endothelial growth factor receptor, and epiderm
211 as platelet-derived growth factor receptor, vascular endothelial growth factor receptor, and epiderm
212 s an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has sh
213 single dose each of plastic microspheres and vascular endothelial growth factor receptor antagonist i
214 l molecule tyrosine kinase inhibitors of the vascular endothelial growth factor receptor are under in
216 Rats with pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and
217 NA1 receptor, EphA2, versus control animals, vascular endothelial growth factor receptor blockade and
218 (obese ZSF1) with the combined treatment of vascular endothelial growth factor receptor blocker SU54
219 After a single subcutaneous injection of the vascular endothelial growth factor receptor blocker Suge
220 eted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor, c-KIT, and
221 b), a multikinase inhibitor of AXL, MET, and vascular endothelial growth factor receptor currently in
222 ese data provide a basis for the activity of vascular endothelial growth factor receptor-directed the
223 he tyrosine kinase inhibitors targeting RET, vascular endothelial growth factor receptor, epidermal g
224 duced cellular proliferation, migration, and vascular endothelial growth factor receptor expression a
225 lar endothelial growth factor and of soluble vascular endothelial growth factor receptor Flt1 (sFlt1)
226 critical for vascular development, including vascular endothelial growth factor receptors Flt1 and Fl
228 nucleotide polymorphisms in the 3'UTR of the vascular endothelial growth factor receptor/FLT1, E2F2 a
229 receptor, mammalian target of rapamycin, and vascular endothelial growth factor receptor have all sho
230 cular endothelial growth factor signaling by vascular endothelial growth factor receptor inhibition m
231 mycin analogue (everolimus) and an epidermal/vascular endothelial growth factor receptor inhibitor (A
232 0% O(2)) after subcutaneous injection of the vascular endothelial growth factor receptor inhibitor SU
233 may potentially benefit from small-molecule vascular endothelial growth factor receptor inhibitor th
234 ted to evaluate trebananib plus sunitinib, a vascular endothelial growth factor receptor inhibitor, i
235 eceived 80 mg of sorafenib, a Raf kinase and vascular endothelial growth factor receptor inhibitor, p
236 ioma-derived endothelial cells, defects in a vascular endothelial growth factor receptor/integrin com
237 ltiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTR
238 ulti-tyrosine kinases inhibitor that targets vascular endothelial growth factor receptor, MET and AXL
239 the epidermal growth factor receptor and the vascular endothelial growth factor receptor on tumor cel
240 of epidermal growth factor receptor family, vascular endothelial growth factor receptor or DNA damag
242 PTC patients showed a reduction in levels of vascular endothelial growth factor receptor phosphorylat
243 b are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-de
244 nhibited by sorafenib, including Raf kinase, vascular endothelial growth factor receptors, platelet-d
245 observed that short-term treatment with the vascular endothelial growth factor receptor/platelet-der
246 rin and metalloprotease domain 17 (ADAM-17), vascular endothelial growth factor receptors, Polo-like
247 gand for platelet-derived growth factor- and vascular endothelial growth factor-receptor (Pvr) homolo
248 l glomerular lesion is mediated by a soluble vascular endothelial growth factor receptor that deprive
249 endothelial growth factor receptor (VEGFR), vascular endothelial growth factor receptor type 1 (VEGF
250 ecular imaging using clinically translatable vascular endothelial growth factor receptor type 2 (VEGF
251 study, the possible localization and role of vascular endothelial growth factor receptor type 2 (VEGF
252 lial growth factor receptor type 1 (VEGFR1), vascular endothelial growth factor receptor type 2 (VEGF
253 afts and to investigate treatment effects on vascular endothelial growth factor receptor type 2 (VEGF
254 of vascular endothelial growth factor-a and vascular endothelial growth factor receptor type 2 in th
255 growth factor receptor type 2 (VEGFR2), and vascular endothelial growth factor receptor type 3 (VEGF
256 tential strategy to circumvent resistance to vascular endothelial growth factor receptor tyrosine kin
258 e therapies revolve around inhibition of the vascular endothelial growth factor receptor tyrosine kin
261 angiogenesis and lymphangiogenesis involving vascular endothelial growth factor-receptor tyrosine kin
263 s an oral tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR) -1,
265 Mutations in the RET proto-oncogene and vascular endothelial growth factor receptor (VEGFR) acti
266 Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR) and
267 ib are oral multikinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) and
268 nyl)ureas that potently inhibited a panel of vascular endothelial growth factor receptor (VEGFR) and
269 Many potent small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR) and
270 4-position that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and
271 angiogenic receptor tyrosine kinases (RTKs)--vascular endothelial growth factor receptor (VEGFR) and
272 vascular endothelial growth factor (VEGF) to vascular endothelial growth factor receptor (VEGFR) and
274 RECENT FINDINGS: Recent studies with oral vascular endothelial growth factor receptor (VEGFR) inhi
275 epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) inhi
276 er and activator of transcription (STAT) and vascular endothelial growth factor receptor (VEGFR) sign
282 use epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and
283 Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epi
284 eted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), pla
285 tions from vascular tumors were stained with vascular endothelial growth factor receptor (VEGFR), vas
286 of vascular endothelial growth factor-A and vascular endothelial growth factor receptor (VEGFR)-2 an
288 tion of phospholipase Cgamma1 (PLCgamma1) by vascular endothelial growth factor receptor (VEGFR)-2 is
290 othelial cells, CD47 interacts directly with vascular endothelial growth factor receptor (VEGFR)-2, a
291 time course, distribution, and dependence on vascular endothelial growth factor receptor (VEGFR)-2/VE
292 tors were isolated by FACS for expression of vascular endothelial growth factor receptor (VEGFR)2 and
293 nib, an oral, potent, selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1,
294 an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1,
295 hibitor targeting Raf and other kinases (ie, vascular endothelial growth factor receptor [VEGFR], pla
296 othelial growth factor-A (VEGF-A) acts via 2 vascular endothelial growth factor receptors, VEGFR-1 an
297 plex consisting of PECAM-1, VE-cadherin, and vascular endothelial growth factor receptors (VEGFRs) th
298 , oral small-molecule inhibitor of all three vascular endothelial growth factor receptors (VEGFRs).
299 arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs).
300 ndothelial growth factor with bevacizumab or vascular endothelial growth factor receptor with oral ty
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。